Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Risa Kurimoto-Tsuruta"'
Autor:
Yuya Ogata, Harumi Kanazawa, Macias Alba, Norikazu Ohtake, Allan E. Surgenor, Iichiro Takata, Hajime Takashima, Walmsley David, Kiyoko Fujita, Hayley Angove, Kunihiko Iwamoto, Masashi Mima, Hiroyuki Sugiyama, Fumihito Ushiyama, Junya Yamagishi, Yousuke Yamada, Alan P. Robertson, Kosuke Hitaka, Koichiro Nakano, Hayato Watanabe, Atsushi Okada, Yohei Matsuda, Roderick E. Hubbard, Nozomi Tanaka-Yamamoto, Toru Yamaguchi-Sasaki, Risa Kurimoto-Tsuruta, Lisa Baker, Akihiro Tanaka, R. Harris
Publikováno v:
Journal of medicinal chemistry. 63(23)
UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) is a zinc metalloenzyme that catalyzes the first committed step in the biosynthesis of Lipid A, an essential component of the cell envelope of Gram-negative bacteria. The most advanced, disclosed Lp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::019ee8a95fea26f38a355f0054fb803d
https://pubmed.ncbi.nlm.nih.gov/33210531
https://pubmed.ncbi.nlm.nih.gov/33210531
Autor:
Yuya Ogata, Nozomi Tanaka-Yamamoto, Naoki Sasamoto, Iichiro Takata, Katsumasa Otake, Hajime Takashima, Yohei Matsuda, Haruhiro Yamashita, Mayumi Endo, Kiyoko Fujita, Kaori Ueki, Masashi Mima, Satoshi Tsuji, Hirotoshi Okumura, Hiroyuki Sugiyama, Fumihito Ushiyama, Risa Kurimoto-Tsuruta
Publikováno v:
Bioorganicmedicinal chemistry. 30
Infectious diseases caused by resistant Gram-negative bacteria have become a serious problem, and the development of therapeutic drugs with a novel mechanism of action and that do not exhibit cross-resistance with existing drugs has been earnestly de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5917a1ea67529b22ac1ee7b5021a36ec
https://pubmed.ncbi.nlm.nih.gov/33385955
https://pubmed.ncbi.nlm.nih.gov/33385955
Autor:
Risa Kurimoto-Tsuruta, Seiken Tokura, Kosuke Kanuma, Yuya Ogata, Tamaoki Tomokazu, Hiroyuki Sugiyama, Takanori Kawaguchi, Kaho Arikawa, Takeuchi Tomoki, Nozomi Tanaka-Yamamoto, Toru Yamaguchi-Sasaki, Atsushi Okada, Ippei Yoshida, Tomoko Abe-Kumasaka, Yutaka Sugaya, Ryo Takahashi, Mitsukane Yoshinaga
Publikováno v:
Bioorganic & Medicinal Chemistry. 28:115818
The development of effective respiratory syncytial virus (RSV) fusion glycoprotein (F protein) inhibitors against both wild-type and the D486N-mutant F protein is urgently required. We recently reported a 15-membered macrocyclic pyrazolo[1,5-a]pyrimi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0be8dcf9dd71a57ac79ad406331fb1
https://doi.org/10.1016/j.bmc.2020.115818
https://doi.org/10.1016/j.bmc.2020.115818